From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Optibiotix – what is the point of a lock in agreement? Even a signed agreement from Steve O'Hara is worth jack shit

By Tom Winnifrith | Friday 19 March 2021


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I think Optibiotix (OPTI) shares are very cheap as are those of Skinbiotherapeutics (SBTX) and am a loyal shareholder in both expecting to treble my money from here. Nor do I begrudge Optibiotix selling a few shares in Skinbiotherapeutics as it announced it had today as I imagine that will more than pay for a Nasdaq listing which may drive a re-rate. But I suggest that, in light of today’s events, a document signed by Steve O’Hara and Nomad and broker Cenkos is a worthless piece of toilet paper and both have legged over and deceived investors in Skinbiotherapeutics. Let me explain.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

PICH

Pitch Pit – this stinks

 

GEX

Georgina Energy: Lyin’ Yet again

Time left: 13:15:55